Undisclosed c-MYC RNA modulator / Ribometrix - LARVOL DELTA

Ribometrix Presents First c-MYC Data Validating RNA-Targeting Platform and Demonstrates Synergistic Potential of eIF4E Program at AACR 2024 (Businesswire) - "First data disclosure from Ribometrix’s RNA-targeting drug discovery platform identifies small molecules targeting c-MYC, a validated but historically undruggable cancer driver. Data shows direct binding of small molecules to c-MYC RNA and reduction of associated protein levels – longtime goal of RNA therapeutic development."

Preclinical • Oncology